777 Service Details:
Service Item
Deliverables
Duration
QC
Gene synthesis, cloning and plasmid prep all included
20 mL CHO/HEK293 500 mL CHO/HEK293
3-10 mg, average 4.5 mg after 2-step purification 100-500 mg
3 weeks
A280, Caliper (R/NR) or SDS-PAGE (R/NR), SEC-HPLC, and endotoxin (<0.5 EU/mg) SEC-HPLC 7.922
1.dx
100 150 200 250 300 350 400
3 weeks
Additional QC
RP-HPLC, bioburden, DSF, DSC, SPR, LC/MS, SEC-MALS, peptide mapping, glycan profiling, cIEF, CHO HCP, residual DNA, ELISA, Western blot, freeze thaw study, micro-developability testing
6.911
50
0
0.5 1 1.5 2 2.5 3 3.5
44.555.566.5 7
7.5 8 8.5 9 9.5 10 10.5 11 11.5 12 12.5 13 13.5 14 14.5 15
Time (min)
Signal:
DAD1A, Sig=280,4 Ref=o
Name RT (min) 6.911 7.922
Width (min) 0.40 0.33 Sum
Area 23.50
Height 0.79 389.44
Area% 0.28 99.72
Case Study: High-Purity mAb Production Confirmed by SEC-HPLC and Caliper-SDS Data
8365.79 8389.29
In this case, the purity of vanilla antibodies produced in 777 platform showed high purity.
Caliper-SDS
SEC-HPLC
1.dx
Caliper-SDS NR
7.922
100 150 200 250 300 350 400
[Labchip_2021-11-09_18-24-41/A3] 1 NR
99.41
LM % Purity Type
1000 1200
0 200 400 600 800
Xsys
0.59
Xsys
x
6.911
50
0
15
20
25
30
35
40
0.5 1 1.5 2 2.5 3 3.5
44.555.566.5 7
7.5 8 8.5 9 9.5 10 10.5 11 11.5 12 12.5 13 13.5 14 14.5 15
Aligned Time (sec)
Time (min)
Signal:
DAD1A, Sig=280,4 Ref=o
Caliper-SDS R
Name RT (min) 6.911 7.922
Width (min) 0.40 0.33 Sum
Area 23.50
Height 0.79 389.44
Area% 0.28 99.72
[Labchip_2021-11-09_18-24-41/E3] 1 Reduce
68.06
% Purity Type
8365.79 8389.29
1000 1200 1400 1600
31.94
LM
400 600 800
Xsys
Caliper-SDS
0 200 -200
Caliper-SDS NR
15
20
25
30
35
40
[Labchip_2021-11-09_18-24-41/A3] 1 NR
Aligned Time (sec)
99.41
LM % Purity Type
1000 1200
0 200 400 600 800
Xsys
0.59
Xsys
x
15
20
25
30
35
40
Aligned Time (sec)
Caliper-SDS R
[Labchip_2021-11-09_18-24-41/E3] 1 Reduce
68.06
% Purity Type
1000 1200 1400 1600
31.94
LM
Learn more: Protein Sciences: HTP Production of High-Quality Vanilla Antibodies
About WuXi Biologics
400 600 800
Xsys
WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model. 15 20 25 30 35 40 Aligned Time (sec) 0 200 -200
The world’s leading global single-source platform from concept to commercialization.
wuxibiologics.com | info@wuxibiologics.com
5-9-2024
Powered by FlippingBook